These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12565772)

  • 1. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?
    Friedrich MG; Hellstern A; Toma MI; Hammerer P; Huland H
    Eur Urol; 2003 Feb; 43(2):146-50; discussion 150-1. PubMed ID: 12565772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
    Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
    J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
    Toma MI; Friedrich MG; Hautmann SH; Jäkel KT; Erbersdobler A; Hellstern A; Huland H
    World J Urol; 2004 Jun; 22(2):145-9. PubMed ID: 14991320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
    Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
    J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Cancer; 2001 Dec; 92(11):2820-8. PubMed ID: 11753955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
    Golijanin D; Sherman Y; Shapiro A; Pode D
    Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
    Serretta V; Pomara G; Rizzo I; Esposito E
    Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
    Sun Y; He H; Ma Q; Wang XY; Yang L; He DL
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2507-12. PubMed ID: 16321281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.
    Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
    J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
    J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
    J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.